Sana Biotechnology Inc

In a Stage 2 advancing environment, the medium-term bias remains bullish with intact higher highs and higher lows. However, price is currently extended and overbought—trading well above the rising EMAs with RSI and Options Score at stretched levels. Short-term timing is unfavorable for new longs; recommended approach is to stalk pullbacks into the rising EMA support zone (9/21/50) to participate at lower risk.

• ↑Zacks Rank #2 (Buy) with $8.57 12-month target (~135% upside).
• ↑14-month diabetes follow-up data in NEJM boosts clinical credibility.
• ↓Weak profitability metrics raise questions on operational efficiency.